top of page

Latest News

texture_bg.jpg

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

ALISO VIEJO, Calif., October 14, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced interim 24-month data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (the BIM-IOL System). The BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to SpyGlass Pharma’s intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Technology

Tel: 949-284-6904

About

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

Investors

CONTACT US

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

© 2025 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page